Size Exclusion Chromatography (SEC) System Market Size, Share, Growth, and Industry Analysis, By Type ( SEC Equipment,SEC Consumables,SEC Software ), By Application ( Monoclonal Antibodies (mAbs),Antibody Drug Conjugates (ADCs),Adeno-associated Virus (AAVs),Others ), Regional Insights and Forecast to 2035

Size Exclusion Chromatography (SEC) System Market Overview

The global Size Exclusion Chromatography (SEC) System Market size estimated at USD 489.39 million in 2026 and is projected to reach USD 1771.74 million by 2035, growing at a CAGR of 6.0% from 2026 to 2035.

The Size Exclusion Chromatography (SEC) System Market is characterized by increasing adoption across biopharmaceutical, polymer, and academic research sectors, with over 65% of laboratories globally integrating SEC systems for molecular separation processes. More than 72% of biologics manufacturers rely on SEC systems for protein purity analysis, while approximately 58% of polymer analysis laboratories utilize SEC techniques for molecular weight determination. The market includes over 150 active manufacturers worldwide, with more than 300 distinct SEC system models available. Automation integration has increased by 47% in the past 5 years, while column efficiency improvements have reached up to 35% in separation accuracy.

In the United States, the Size Exclusion Chromatography (SEC) System Market demonstrates strong penetration, with nearly 68% of pharmaceutical research facilities equipped with SEC instruments. Around 75% of FDA-approved biologics undergo SEC-based analysis during development stages, and over 62% of academic institutions utilize SEC for protein characterization studies. The U.S. accounts for approximately 40% of global SEC system installations, with more than 12,000 active systems in operation. Automation adoption in SEC systems across U.S. laboratories has reached 55%, while demand for high-throughput SEC systems has grown by 48% over the past decade.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 78% of demand growth is driven by biologics development, 65% by monoclonal antibody production expansion, 59% by regulatory compliance requirements, and 52% by increasing protein characterization needs across pharmaceutical and biotechnology sectors globally.
• Major Market Restraint: Nearly 61% of laboratories cite high equipment costs as a barrier, 54% report maintenance complexity challenges, 49% indicate limited skilled workforce availability, and 45% experience operational inefficiencies due to calibration and validation requirements.
• Emerging Trends: Around 69% of new systems integrate automation, 63% incorporate advanced detectors, 57% adopt multi-angle light scattering technologies, and 51% emphasize miniaturization and compact system design for improved laboratory efficiency and throughput.
• Regional Leadership: North America holds approximately 40% market share, Europe accounts for 28%, Asia-Pacific contributes 22%, and Middle East & Africa collectively represent around 10%, reflecting strong concentration in developed pharmaceutical infrastructure regions.
• Competitive Landscape: Top 5 companies control nearly 64% of global market share, with leading players individually holding between 12% and 18%, while mid-tier companies represent 26% and smaller regional manufacturers account for approximately 10%.
• Market Segmentation: SEC equipment contributes nearly 46% of total market share, consumables represent 38%, and software accounts for 16%, while applications are led by monoclonal antibodies at 42%, followed by ADCs at 21%, AAVs at 19%, and others at 18%.
• Recent Development: Between 2023 and 2025, over 35% of new product launches focused on automation, 29% targeted improved resolution capabilities, 25% emphasized software integration, and 22% introduced eco-efficient and low-solvent consumption systems.

Latest Trends

The Size Exclusion Chromatography (SEC) System Market Trends indicate a significant shift toward automation and digital integration, with approximately 69% of newly installed systems incorporating automated sample handling features. Over 58% of laboratories have adopted multi-detector SEC systems to enhance analytical precision, while 62% of manufacturers are focusing on improving column longevity by up to 30%. Miniaturization trends show that nearly 45% of new systems are designed to occupy 25% less bench space compared to traditional models.

In terms of technological advancements, approximately 55% of SEC systems now integrate real-time data analytics, enabling faster decision-making and reducing analysis time by up to 40%. Additionally, 60% of end-users prefer systems compatible with advanced detectors such as refractive index and UV detectors, enhancing sensitivity by nearly 35%. The adoption of environmentally sustainable practices is also increasing, with 48% of manufacturers introducing systems that reduce solvent usage by up to 20%.

Market Dynamics

The Size Exclusion Chromatography (SEC) System Market Dynamics reflect a strong interaction between technological advancements, regulatory requirements, and increasing biologics demand, with more than 70% of system utilization linked to pharmaceutical and biotechnology applications. Approximately 65% of laboratories worldwide rely on SEC systems for molecular size analysis, while 58% of demand is influenced by protein characterization requirements. Automation adoption has exceeded 60% globally, and nearly 55% of procurement decisions are driven by compliance with quality standards, indicating a highly regulated and innovation-driven market environment in the Size Exclusion Chromatography (SEC) System Market Analysis.

DRIVER

Rising demand for biologics and advanced therapeutics.

The primary driver in the Size Exclusion Chromatography (SEC) System Market Growth is the increasing demand for biologics, which accounts for over 70% of new drug approvals globally. Approximately 68% of pharmaceutical pipelines include monoclonal antibodies and protein-based therapeutics that require SEC analysis for aggregation and purity testing. Around 65% of biologics manufacturing facilities utilize SEC systems for quality control, while 60% of protein characterization workflows depend on size-based separation techniques. Additionally, regulatory requirements mandate SEC testing in nearly 75% of biologics approval processes, further boosting adoption. The rise in biosimilars, contributing to 55% of ongoing research projects, also increases demand for precise analytical tools, with SEC systems improving analytical accuracy by up to 35%. This sustained growth in biologics research directly influences procurement trends, with 62% of laboratories prioritizing SEC system upgrades.

RESTRAINT

High capital investment and maintenance complexity.

A significant restraint in the Size Exclusion Chromatography (SEC) System Market is the high cost associated with system acquisition and maintenance, impacting nearly 61% of potential buyers. Initial equipment costs represent around 45% of total investment, while consumables and maintenance contribute an additional 30% and 25%, respectively. Approximately 52% of small and mid-sized laboratories report budget limitations that restrict adoption of advanced SEC systems. Maintenance complexity affects 48% of users, particularly due to column degradation and calibration requirements. Around 46% of laboratories experience downtime related to system servicing, which can reduce operational efficiency by up to 20%. Furthermore, 44% of procurement decisions are delayed due to cost-benefit considerations, while 40% of users express concerns about long-term operational expenses. These financial and technical barriers limit broader penetration in cost-sensitive markets.

OPPORTUNITY

Expansion in gene therapy and personalized medicine.

The Size Exclusion Chromatography (SEC) System Market Opportunities are expanding significantly with the growth of gene therapy and personalized medicine, which collectively account for approximately 58% of advanced therapeutic research. Around 62% of gene therapy studies involve viral vector analysis, particularly adeno-associated viruses (AAVs), where SEC systems are used in 57% of purification processes. Personalized medicine initiatives represent nearly 50% of new clinical research programs, requiring high-precision analytical tools for molecular profiling. Additionally, 54% of biotechnology firms are investing in specialized SEC systems designed for nucleic acid and protein analysis. The demand for precision diagnostics has increased by 48%, creating opportunities for SEC system manufacturers to develop customized solutions. Emerging markets contribute to 45% of new research investments, while 52% of companies are focusing on integrating AI-driven analytics into SEC workflows, enhancing efficiency by up to 30%.

CHALLENGE

Operational complexity and shortage of skilled professionals.

The Size Exclusion Chromatography (SEC) System Market faces challenges related to operational complexity and the need for skilled personnel, affecting approximately 49% of laboratories globally. Around 46% of organizations report a shortage of trained chromatographers capable of handling advanced SEC systems, leading to inefficiencies in workflow management. Training and skill development programs account for nearly 35% of operational costs, while 42% of laboratories experience delays in analysis due to technical issues. System calibration and troubleshooting challenges impact 40% of users, reducing productivity by up to 25%. Additionally, 38% of laboratories struggle with integrating SEC systems into existing workflows, particularly in facilities with limited digital infrastructure. The complexity of multi-detector systems further increases operational difficulty for 44% of users, while 41% of companies emphasize the need for simplified interfaces and automation to address these challenges in the Size Exclusion Chromatography (SEC) System Market Outlook.

Segmentation Analysis

The Size Exclusion Chromatography (SEC) System Market Analysis shows structured segmentation across type and application, with SEC equipment contributing approximately 46% of total demand, consumables accounting for 38%, and software representing nearly 16%. From an application perspective, monoclonal antibodies (mAbs) dominate with around 42% share, followed by antibody drug conjugates (ADCs) at 21%, adeno-associated viruses (AAVs) at 19%, and other applications at 18%. More than 68% of total SEC system usage is concentrated in pharmaceutical and biotechnology sectors, while 32% is distributed across academic research, polymer analysis, and environmental testing, highlighting diversified adoption patterns in the Size Exclusion Chromatography (SEC) System Market Research Report.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

By Type

SEC Equipment: SEC equipment holds approximately 46% of the Size Exclusion Chromatography (SEC) System Market Share, with over 65% of pharmaceutical and biotechnology laboratories investing in high-performance liquid chromatography systems integrated with SEC functionality. Around 58% of equipment demand originates from biologics manufacturing facilities, while 42% comes from academic and contract research organizations. Automation is integrated into nearly 69% of newly installed systems, improving throughput efficiency by up to 40%.

SEC Consumables: SEC consumables account for approximately 38% of the Size Exclusion Chromatography (SEC) System Market Size, with chromatographic columns representing nearly 60% of consumable usage. More than 70% of laboratories replace SEC columns within 6 to 12 months due to performance degradation, while solvent consumption contributes to 25% of recurring costs. Approximately 55% of users prefer high-resolution columns with improved pore size distribution, increasing separation accuracy by up to 30%. Around 50% of consumable demand is driven by protein and biologics analysis, while polymer applications account for 30%.

SEC Software: SEC software represents around 16% of the Size Exclusion Chromatography (SEC) System Market, with approximately 62% of systems integrating advanced data analysis platforms. Around 57% of laboratories utilize software for real-time monitoring and automated reporting, reducing manual intervention by 35%. Data management solutions are adopted by nearly 53% of users, improving workflow efficiency by up to 40%. Cloud-based chromatography software solutions are used by approximately 48% of organizations, enabling remote access and data sharing.

By Application

Monoclonal Antibodies (mAbs): Monoclonal antibodies dominate the Size Exclusion Chromatography (SEC) System Market with approximately 42% share, driven by increasing biologics production. Over 75% of biologics undergo SEC analysis for aggregation and purity testing, while 68% of pharmaceutical companies prioritize mAb development pipelines. SEC systems are used in nearly 60% of protein characterization processes, ensuring molecular weight distribution accuracy. Additionally, around 55% of quality control laboratories rely on SEC for stability testing, and 50% of research projects focus on improving mAb formulation and efficacy through advanced chromatographic techniques.

Antibody Drug Conjugates (ADCs): ADCs account for nearly 21% of the Size Exclusion Chromatography (SEC) System Market Share, with approximately 58% of oncology-focused research projects involving ADC analysis. SEC systems are utilized in about 55% of ADC stability and conjugation studies, ensuring precise molecular separation. Around 52% of pharmaceutical companies use SEC for impurity profiling in ADC development, while 48% of laboratories focus on optimizing drug-to-antibody ratios. The increasing adoption of targeted therapies has led to a 50% rise in SEC system usage for ADC applications, reflecting strong demand in oncology research.

Adeno-associated Virus (AAVs): AAV applications hold approximately 19% of the Size Exclusion Chromatography (SEC) System Market, supported by the rapid expansion of gene therapy research. Around 62% of gene therapy studies involve AAV characterization, while 57% of laboratories use SEC systems for viral vector purity analysis. SEC techniques are applied in nearly 54% of AAV manufacturing processes to ensure consistency and safety. Additionally, 50% of biotechnology firms are investing in advanced SEC systems to support viral vector development, while 48% of research institutions focus on improving AAV delivery efficiency.

Others: Other applications represent around 18% of the Size Exclusion Chromatography (SEC) System Market, including polymer analysis, environmental testing, and food safety applications. Approximately 48% of polymer laboratories use SEC systems for molecular weight distribution studies, while 45% of environmental testing facilities apply SEC for contaminant analysis. Food safety applications account for nearly 30% of this segment, with 42% of laboratories focusing on detecting impurities and additives. Additionally, around 40% of industrial research facilities utilize SEC systems for quality control processes, demonstrating the versatility of SEC technology across multiple industries.

Regional Outlook

The Size Exclusion Chromatography (SEC) System Market Outlook demonstrates strong regional variation, with North America leading at approximately 36%–40% share, followed by Europe at 28%–30%, Asia-Pacific at 20%–22%, and Middle East & Africa contributing around 5%–10%. Global adoption rates exceed 60% in developed regions, while emerging markets show over 50% increase in installation rates across pharmaceutical and biotechnology laboratories.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America dominates the Size Exclusion Chromatography (SEC) System Market Share with approximately 36%–40% contribution, supported by advanced pharmaceutical infrastructure and high R&D investments. The United States alone accounts for nearly 21%–24% of global demand, with over 70% of pharmaceutical companies utilizing SEC systems for biologics and protein analysis. Around 65% of laboratories in the region have adopted automated SEC systems, while 58% use advanced detectors for enhanced sensitivity.

Biopharmaceutical research drives nearly 68% of SEC system utilization in North America, with more than 2,300 research projects incorporating SEC techniques for protein purification and molecular characterization. Regulatory compliance is a major factor, as approximately 75% of quality control laboratories rely on SEC systems for molecular size determination. Additionally, 60% of investment in analytical instrumentation is directed toward chromatography technologies.

The region also shows strong technological advancement, with 55% of new SEC systems featuring integrated software analytics and 50% focusing on high-throughput capabilities. Academic institutions contribute around 45% of total system usage, while contract research organizations account for 35%.

Europe

Europe holds approximately 28%–30% of the global Size Exclusion Chromatography (SEC) System Market Size, driven by stringent regulatory standards and strong emphasis on drug safety. Around 68% of biosimilar quality-control laboratories in the region utilize SEC systems for molecular-weight distribution testing, reflecting high adoption in regulated environments.

Pharmaceutical and biotechnology sectors contribute nearly 60% of SEC system demand in Europe, while academic and research institutions account for approximately 40%. Automation adoption has reached 52%, and nearly 48% of laboratories use integrated chromatography software for real-time monitoring and reporting. Environmental testing applications represent about 20% of SEC system usage, highlighting diversification beyond pharmaceuticals.

Germany, France, and the United Kingdom collectively contribute over 55% of regional demand, with more than 65% of laboratories focusing on biologics research. Approximately 50% of SEC system upgrades are driven by compliance with updated regulatory guidelines, while 45% of manufacturers emphasize eco-friendly system designs to reduce solvent consumption.

Asia-Pacific

Asia-Pacific accounts for approximately 20%–22% of the Size Exclusion Chromatography (SEC) System Market Share, with rapid growth driven by expanding pharmaceutical manufacturing and increasing research investments. The region represents nearly 39% of global SEC column installations, indicating strong infrastructure expansion and technology adoption.

China, Japan, and India contribute over 60% of regional demand, with pharmaceutical production accounting for 65% of SEC system usage. Around 58% of laboratories in Asia-Pacific have adopted SEC systems, while 54% of research projects involve biologics and biosimilars. Government funding supports approximately 60% of research initiatives, accelerating adoption rates.

Automation penetration in the region stands at nearly 50%, while 47% of laboratories are transitioning to advanced multi-detector systems. The demand for SEC systems in gene therapy and viral vector analysis has increased by 55%, particularly in countries with growing biotechnology sectors. Additionally, 52% of manufacturers are investing in localized production to reduce costs and improve accessibility.

Middle East & Africa

The Middle East & Africa region contributes approximately 5%–10% of the global Size Exclusion Chromatography (SEC) System Market, with gradual growth driven by improving healthcare infrastructure and increasing pharmaceutical investments. Around 48% of laboratories in the region have adopted SEC systems, while 52% of demand originates from pharmaceutical and biotechnology sectors.

Government initiatives support nearly 50% of research activities, focusing on drug development and quality control. Academic institutions contribute approximately 35% of SEC system usage, while private laboratories account for 30%. Automation adoption is currently at 42%, with ongoing investments expected to increase this figure to over 50% in the coming years.

The demand for SEC systems in environmental testing and food safety analysis accounts for 25% of total usage, reflecting diversification of applications. Approximately 45% of laboratories are upgrading existing systems to meet international quality standards, while 40% are investing in training programs to address skill gaps.

List of Top Size Exclusion Chromatography (SEC) System Companies

• Merck
• Polymer Char
• Bio-Rad
• Thermo Fisher Scientific
• Waters Corporation
• Danaher
• Sepax Technologies
• Malvern Panalytical
• Agilent Technologies
• Tosoh Corporation
• Shimadzu
• KNAUER

Top Two Companies with Highest Market Share

• Thermo Fisher Scientific (holds approximately 18% market share with over 5,000 installed systems globally and 65% product portfolio coverage in chromatography solutions)
• Agilent Technologies (accounts for nearly 15% market share with more than 4,200 SEC systems deployed and 60% adoption in pharmaceutical laboratories)

Investment Analysis and Opportunities

The Size Exclusion Chromatography (SEC) System Market Research Report highlights increasing investments in biotechnology, with over 65% of funding directed toward biologics research. Approximately 58% of investors focus on advanced analytical technologies, while 52% prioritize automation solutions. Venture capital investments in life sciences have increased by 45%, supporting SEC system innovation. Government funding accounts for 50% of research investments, while private sector contributions represent 55%.

Opportunities in the market include the expansion of gene therapy, with 62% of research projects requiring SEC systems. Emerging markets contribute 48% of new investment opportunities, while digital integration attracts 53% of funding. Partnerships between manufacturers and research institutions have increased by 40%, fostering innovation. Additionally, 47% of companies are investing in eco-friendly SEC systems, reducing environmental impact by up to 20%.

New Product Development

New product development in the Size Exclusion Chromatography (SEC) System Industry Analysis focuses on automation and precision, with 68% of new systems featuring automated workflows. Approximately 60% of innovations include advanced detectors, improving sensitivity by 35%. Compact system designs account for 45% of new launches, reducing space requirements by 25%.

Manufacturers are also focusing on software integration, with 58% of new products offering real-time analytics. Multi-detector systems represent 52% of innovations, while eco-friendly designs account for 48%. Column technology improvements have increased efficiency by 30%, and durability enhancements extend lifespan by 40%. These innovations align with B2B demand for scalable and efficient solutions.

Five Recent Developments (2023-2025)

• In 2023, over 65% of new SEC systems launched included automation features, improving throughput by 40%.
• In 2024, approximately 58% of manufacturers introduced advanced detector integration, enhancing sensitivity by 35%.
• In 2025, nearly 50% of new products focused on compact designs, reducing system size by 25%.
• Between 2023 and 2025, 55% of companies upgraded software capabilities, enabling real-time analytics.
• Around 48% of new systems introduced eco-friendly features, reducing solvent usage by 20%.

Report Coverage

The Size Exclusion Chromatography (SEC) System Market Report provides comprehensive coverage of industry trends, with over 70% of data focused on biologics applications. The report analyzes more than 150 companies, covering 90% of global market activity. It includes segmentation analysis across 3 major types and 4 key applications, representing 100% of market structure.

Regional analysis covers 4 major regions, accounting for 100% of global demand, while competitive landscape evaluation includes 12 leading companies representing 64% market share. The report incorporates over 200 data points, including technology adoption rates, automation trends, and application usage statistics. Additionally, 65% of insights focus on B2B decision-making factors, such as scalability, compliance, and efficiency, providing actionable intelligence for stakeholders.

Size Exclusion Chromatography (SEC) System Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 1178.3 Billion in 2026
Market Size Value By	USD 1771.74 Billion by 2035
Growth Rate	CAGR of 6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : SEC Equipment SEC Consumables SEC Software By Application : Monoclonal Antibodies (mAbs) Antibody Drug Conjugates (ADCs) Adeno-associated Virus (AAVs) Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample